Article Text

This article has a correction. Please see:

Download PDFPDF
Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure
  1. Tin Aung1,
  2. Paul T K Chew1,2,
  3. Francis T S Oen1,
  4. Yiong-Huak Chan3,
  5. Lennard H Thean1,
  6. Leonard Yip1,
  7. Boon-Ang Lim1,
  8. Steve K L Seah1
  1. 1Singapore National Eye Centre
  2. 2National University of Singapore
  3. 3Clinical Trials and Epidemiology Research Unit, Singapore
  1. Correspondence to: Professor P T K Chew, Department of Ophthalmology, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074; ophchewp{at}nus.edu.sg

Abstract

Aims: To assess the additive effect of unoprostone and latanoprost in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT)

Methods: 32 patients with POAG or OHT were randomised to receive either latanoprost once daily or unoprostone twice daily for 4 weeks. After 4 weeks, all patients received both latanoprost and unoprostone for another 4 weeks. The IOP was measured at 9 am and 5 pm on the baseline, day 28, and day 56 visits, and at 9 am on day 14 and day 42 visits. The medications were given to the patients in an open label fashion. The observer was masked to the treatment given. The mean of the measurements was calculated. Safety parameters were also recorded. The additive effect of the medications was assessed by the reduction in intraocular pressure (IOP) when both medications were used, compared with when one medication was used.

Results: 28 patients completed both treatment periods and had IOP data available for evaluation. After 1 month of treatment, latanoprost significantly reduced IOP (mean by 6.1 (SEM 0.8) mm Hg (p<0.001) and unoprostone by 4.9 (1.0) mm Hg (p<0.001) from the baseline of 24.4 (0.6) mm Hg and 24.4 (1.1) mm Hg respectively (p = 0.18). When latanoprost once daily was given to patients treated with unoprostone, there was additional IOP lowering of 1.9 (0.6) mm Hg (p = 0.012). However, adding unoprostone to those being treated with latanoprost produced an IOP change of +0.4 (0.5) mm Hg (p = 0.42). Ocular symptoms and findings were mild and equally distributed between treatment groups, and after combined therapy. Hyperaemia and ocular irritation were the most frequently reported events. Over a third of patients experienced ocular irritation with the combination of medications.

Conclusions: Latanoprost once daily causes additional IOP lowering in eyes which were being treated with unoprostone twice a day. However, there was no additional IOP lowering when unoprostone was added to eyes which were being treated with latanoprost. Both drugs were well tolerated together with few ocular adverse events.

  • latanoprost
  • unoprostone
  • glaucoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Linked Articles

  • Correction
    BMJ Publishing Group Ltd.BMA House, Tavistock Square, London, WC1H 9JR